MOTS-C: The Mitochondrial Peptide at the Center of Longevity Research
MOTS-C (Mitochondrial Open reading frame of the twelve S rRNA type-C) is a 16-amino-acid bioactive peptide — sequence: MRWQEMGYIFYPRKLR — encoded not by nuclear DNA, but by the mitochondrial genome, specifically within the 12S ribosomal RNA region. CAS 1627580-76-4. This makes MOTS-C one of a small class of mitochondria-derived peptides (MDPs) — alongside humanin and SHLP1-6 — that blur the traditional boundary between mitochondria as passive energy producers and mitochondria as active endocrine signaling organelles. MOTS-C is increasingly central to longevity, metabolic, and exercise physiology research.
How MOTS-C Is Made: Mitochondrial Genome Encoding
Human mitochondrial DNA (mtDNA) is a 16.5 kb circular genome traditionally thought to encode only 13 proteins (all components of the respiratory chain/ATP synthase), 22 tRNAs, and 2 rRNAs. The discovery of MOTS-C required re-examining this assumption: the MOTS-C sequence is encoded within the 12S rRNA region as a small open reading frame (sORF) that had been functionally invisible in conventional genomic analysis.
MOTS-C is evolutionarily conserved across primates, suggesting functional importance that natural selection has maintained across millions of years. Circulating MOTS-C levels are detectable in human plasma and show a strong inverse correlation with age — younger individuals and high-fitness individuals have substantially higher circulating MOTS-C than sedentary older adults. This age-dependent decline is a core driver of longevity research interest.
Mechanism: AMPK Activation via the Folate Cycle
MOTS-C’s molecular mechanism involves a compelling cellular pathway: it enters the nucleus under metabolic stress conditions and inhibits folate cycle enzymes, specifically 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) accumulation. AICAR is an endogenous AMP-kinase (AMPK) activator — the same pathway activated by the diabetes drug metformin. MOTS-C thus functions as an endogenous AMPK activator that mimics the downstream metabolic effects of aerobic exercise: increased glucose uptake, enhanced fatty acid oxidation, improved insulin sensitivity, and mitochondrial biogenesis.
This exercise-mimetic action is why MOTS-C appears across both metabolic and longevity research contexts simultaneously. The AMPK/PGC-1α axis that MOTS-C activates is one of the most conserved longevity-promoting pathways identified in model organisms from C. elegans to mammals, and one that naturally declines with aging.
Longevity Research Findings
A landmark 2021 study in Nature Aging (Lee et al.) demonstrated that MOTS-C administration to aged mice improved physical performance, enhanced insulin sensitivity, and extended median lifespan — with effects concentrated in older animals experiencing the natural age-related decline in endogenous MOTS-C. Younger animals with already-high endogenous MOTS-C showed attenuated responses, consistent with a compensatory-supplementation model.
Additional research has linked MOTS-C to reduced cellular senescence markers, improved mitochondrial function in aged tissues, and protection against metabolic dysfunction under high-fat-diet conditions. Its action in skeletal muscle — promoting GLUT4 translocation and improving glucose disposal — has generated interest from both metabolic disease and exercise science researchers.
Why 10mg, 20mg, and 40mg Sizes Exist
Combat Research supplies MOTS-C in three quantities: 10 mg for pilot and validation protocols, 20 mg for extended research runs requiring multiple timepoints, and 40 mg for high-throughput studies or longitudinal research across multiple animal cohorts. All three are verified at ≥99% HPLC purity with CoA per batch.
Frequently Asked Questions — MOTS-C
What does MOTS-C stand for?
MOTS-C stands for Mitochondrial Open reading frame of the twelve S rRNA type-C. It is named for its unique genomic origin within the mitochondrial 12S ribosomal RNA region.
How does MOTS-C differ from other longevity peptides like BPC-157 or IGF-1 LR3?
MOTS-C is an endogenous mitochondria-derived peptide with a systemic exercise-mimetic mechanism via AMPK activation. BPC-157 is a synthetic gastric peptide focused on tissue repair and angiogenesis. IGF-1 LR3 is a growth factor analog driving PI3K/Akt/mTOR anabolic signaling. Each targets entirely different biology with minimal overlap.
Is MOTS-C related to metformin?
Mechanistically, yes. Both activate AMPK via related upstream pathways — metformin through mitochondrial complex I inhibition; MOTS-C through folate cycle-mediated AICAR accumulation. This convergence on AMPK has led researchers to study MOTS-C as a more physiologically native AMPK activator with potentially different tissue distribution than metformin.
